CERENOME Secures Up to $20 Million Royalty-Based Credit Facility

The CNS oncology company got initial funding at closing from 3i Fund and says its cash runway now extends well into 2028.

Share
Cerenome's CNSide platform analyzes cerebrospinal fluid to detect cancer cells in the central nervous system.